ClinicalTrials.gg
RecruitingNCT07427043ROPESUpdated May 22, 2026

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

A Phase 3 interventional study of multimodal analgesia pathway with up-front small opioid prescription and multimodal analgesia pathway without up-front small opioid prescription in Opioid Consumption, Postoperative, Multimodal Analgesia and Robotic Assisted Laparoscopic Surgery, sponsored by Brigham and Women's Hospital. Recruiting at 2 sites in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Brigham and Women's Hospital · Phase 3, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital — 9 open to participants now, 12 under way, 1 of them phase 3. Prostatic Neoplasms · Brigham and Women's Hospital.

Planned enrollment
2nd of 15
300 · median 36
Started
2026
with 3 others
Phase 3
Only one
of the 16
Primary completion
2026-12
later than 2 of 11 live
Registered
14th of 16
by date

Among the 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients are counseled on post-operative pain management and then may opt into or out of the study with randomization to discharge prescriptions including (A) multimodal plan with additional automatic opioid prescription or (B) multimodal plan alone and instruction to call phone line to request opioid prescription if pain management is insufficient. Additionally, a cohort of historical controls prior to implementation of the study is also prospectively assessed as a pre-study baseline. The primary outcome is postoperative opioid consumption. Secondary outcomes include bowel function recovery, unplanned care encounters including emergency department visits or postoperative phone calls, and same-day discharge rates.

Read the detailed description

The Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) study will implement and systematically evaluate an opioid-free discharge pathway (OFP) after robotic-assisted laparoscopic prostatectomy (RALP) at Brigham and Women's Hospital and Brigham \& Women's Faulkner Hospital. Patients are counseled pre-operatively and offered participation. Data will be compared across three prospectively studied groups: pre-implementation historical baseline (current practice), post-implementation ROPES with multimodal analgesia pathway alone (which requires patients to call phone line after discharge to request opioid if pain uncontrolled), and post-implementation ROPES with multimodal analgesia pathway plus up-front small opioid prescription. Standardized multimodal analgesic therapy is provided to all participating patients following study implementation, with opioids used only as needed. There is no change to the surgery and anesthesia plan (though standard care at our center includes injection of local anesthetic to incisions and ketorolac is encouraged at end of the procedure), and patients are allowed opioids while admitted to the post-op recovery area. The study aims to reduce postoperative opioid use while maintaining safety and quality outcomes; this will assess non-inferiority of ROPES OFP in comparison to standard opioid prescribing. Results may inform wider practice change within both our center, the field of urology, and perhaps surgical care more broadly.

03

Conditions studied

  • Opioid Consumption, Postoperative
  • Multimodal Analgesia
  • Robotic Assisted Laparoscopic Surgery
  • Robotic Assisted Laparoscopic Radical Prostatectomy
  • Prostate Cancer

Browse trials for

Keywords

  • Multimodal Analgesia
  • Robotic Assisted Laparoscopic Radical Prostatectomy
  • Postoperative Opioid Consumption
  • Localized Prostate Cancer
  • Robotic Assisted Laparoscopic Surgery
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ≥45 years old
  • Undergoing Robotic Assisted Laparoscopic Prostatectomy (RALP) at BWH or BWFH
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney disease (baseline Cr >1.3)
  • NSAID /allergy
  • Regular opioid use or substance abuse prior to surgery
  • Inability to provide their own consent
  • Deviation from standard surgical practice for RALP (e.g. major complication requiring operative intervention that would result in patient no longer being considered a routine case)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Pre-implementation historical baseline - Standard care prior to study intervention

    Standard care prior to study intervention

    Drug: pre-implementation baseline including opioid

  • Active comparator
    Post-implementation ROPES with multimodal analgesia pathway alone

    Educated on post-op pain management, multimodal analgesia scripts given but no pre-emptive opioid script (to obtain opioid after discharge patient must call phone line to request).

    Drug: multimodal analgesia pathway without up-front small opioid prescription

  • Active comparator
    Post-implementation ROPES with multimodal analgesia pathway and up-front small opioid prescription

    Educated on post-op pain management, multimodal analgesia scripts given and additionally given pre-emptive standard opioid script.

    Drug: multimodal analgesia pathway with up-front small opioid prescription

Interventions

  • Drugmultimodal analgesia pathway with up-front small opioid prescription

    multimodal analgesia pathway including an up-front small opioid prescription

  • Drugmultimodal analgesia pathway without up-front small opioid prescription

    multimodal analgesia pathway without up-front small opioid prescription

  • Drugpre-implementation baseline including opioid

    pre-implementation baseline including opioid

06

What researchers measure

Primary outcomes

  1. Post-discharge opioid consumption (MME)

    assessed at post-operative visit

    Time frame: 1-2 weeks after surgery

Secondary outcomes

  1. Return of bowel function

    Time frame: 1 week

  2. Emergency Department visits

    Time frame: 30 days

  3. Postoperative phone calls

    Time frame: 30 days

  4. Same-day discharge rate

    Index hospitalization

    Time frame: Day of Surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This trial is being performed at within a single institution (Mass General Brigham) at two of it's constituent sites (BWH and BWFH), as part of IRB approval of the study decision was for privacy policy that only aggregated data would be intended to be shared outside the institutions system and any IPD would be solely stored on HIPAA compliant servers at the facility. De=identified or aggregated data would be permitted to be shared so long as subjects could not be identified.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 9 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 23, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 30, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07427043
Responsible party
Timothy Clinton (Associate Surgeon, Brigham and Women's Hospital) — Principal investigator
First posted
Feb 23, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Timothy Clinton, MD
Contact
tclinton1@bwh.harvard.edu
617-732-6384
Timothy Clinton, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion